- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Adcetris (brentuximab vedotin) / Takeda, Pfizer
Journal: An evolutionary differential game for regulating the role of monoclonal antibodies in treating signalling pathways in oesophageal cancer. (Pubmed Central) - Aug 1, 2024
The analysis and computation of two game-theoretic strategies, Stackelberg and Nash equilibria, are conducted within this framework to ascertain the most favourable outcome for the patient. By comparing Stackelberg equilibria with Nash equilibria, numerical experiments show that the Stackelberg equilibria are superior for treating signalling pathways and are critical for the success of monoclonal antibodies in improving oesophageal cancer patient outcomes.
- |||||||||| Rituxan (rituximab) / Roche
Retrospective data, Journal: Long-term use of rituximab increases T cell count in MS patients. (Pubmed Central) - Aug 1, 2024
The clinical implications of long-term treatment with rituximab and its effect on the T cell pool needs to be explored further. Since no difference in B cell depletion was detected between the two patient groups, 1000mg as an initial dose might be excessive, suggesting a personalized dosing regimen might have therapeutic and financial advantages.
- |||||||||| Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast (clinicaltrials.gov) - Aug 1, 2024
P1/2, N=44, Active, not recruiting,
Enrolling by invitation --> Active, not recruiting Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- |||||||||| Tyvyt (sintilimab) / Eli Lilly
Enrollment closed, Trial completion date, Trial primary completion date: Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. (clinicaltrials.gov) - Aug 1, 2024
P1, N=45, Active, not recruiting,
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Jul 2025 Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Oct 2024
- |||||||||| SAR442257 / Sanofi
Trial completion date: First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL (clinicaltrials.gov) - Aug 1, 2024
P1, N=47, Active, not recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Oct 2024 Trial completion date: Aug 2024 --> Mar 2025
- |||||||||| Opdivo (nivolumab) / BMS, magrolimab (ONO-7913) / Ono Pharma
New P1 trial, Combination therapy, Metastases: An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 1, 2024
P1, N=32, Active, not recruiting,
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date, Pan tumor: MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (clinicaltrials.gov) - Aug 1, 2024
P2, N=610, Active, not recruiting,
Trial completion date: Apr 2025 --> Jul 2025 | Trial primary completion date: Apr 2025 --> Jul 2025 Recruiting --> Active, not recruiting | Trial completion date: Feb 2027 --> Aug 2026 | Trial primary completion date: Feb 2027 --> Aug 2026
- |||||||||| Opdivo (nivolumab) / BMS
Trial suspension, Tumor mutational burden, Metastases: Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (clinicaltrials.gov) - Jul 31, 2024
P3, N=636, Suspended,
Recruiting --> Active, not recruiting | Trial completion date: Feb 2027 --> Aug 2026 | Trial primary completion date: Feb 2027 --> Aug 2026 Active, not recruiting --> Suspended
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
MYSTERY FLUID: MEDICATION-INDUCED PLEURAL EFFUSION (Convention Center Exhibit Hall: Rapid Fire Area 4B) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5624;
Targeted therapies for cancer have become part of standard treatment or clinical trials therefore side effects are more commonly reported. Risks benefits of holding the drugs, anti-inflammatory therapy, low dose resumption or exchange of therapy should be discussed in a multidisciplinary approach.
- |||||||||| Rituxan (rituximab) / Roche
A CASE OF IGG4-RELATED DISEASE INVOLVING THE LUNGS REQUIRING MULTIPLE BIOPSIES FOR DIAGNOSIS (Convention Center Exhibit Hall: Poster Area 4) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5606;
In our case, despite multiple methods of lung biopsy being performed, the diagnosis remained unclear. While the presence of plasma cells with positive IgG4 staining on lymph node biopsy and elevated serum levels of IgG4 are useful, they are not specific for IgG4-RD and can be present in other conditions, and should therefore be interpreted with caution.[5]
- |||||||||| Rituxan (rituximab) / Roche
WHY WON'T IT END? A CASE OF PERSISTENT COVID-19 (Convention Center Exhibit Hall: Poster Area 4) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5603;
CASE PRESENTATION: We present a case of a 37 year old female with past medical history of granulomatosis with polyangiitis on bi-annual rituximab who was hospitalized one week prior for COVID-19 with minimal improvement post remdesivir and IV steroids with oral taper that presented to the ED with recurrent dyspnea and a macular, violaceous, non-tender pruritic rash...She was transitioned from rituximab to azathioprine for vasculitis immunosuppression... We highlight this case to shed light on hypogammaglobulinemia as a rare but clinically relevant adverse effect of rituximab as well as the effect of immunoglobulin deficiencies and IVIG administration on persistent viremia in immunosuppressed patients.
- |||||||||| Rituxan (rituximab) / Roche
GRANULOMATOSIS WITH POLYANGIITIS PRESENTING WITH BILATERAL APICAL CAVITATING LUNG MASSES (Convention Center Exhibit Hall: Poster Area 3) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5586;
This unique case of Granulomatosis with Polyangiitis, presenting with rare bilateral apical pulmonary masses, highlights the diagnostic challenges of atypical GPA manifestations. The decisive identification of c-ANCA and PR-3 antibodies, combined with histopathological examination, was crucial in differentiating GPA from other differential diagnoses.
- |||||||||| Rituxan (rituximab) / Roche
CHAI-LIKE DISEASE WITH DIFFUSE ALVEOLAR HEMORRHAGE (Convention Center Exhibit Hall: Poster Area 3) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5581;
Our patient has not fit into diagnostic criteria for CHAI or ALPS but given improvements in his condition there are likely additional autoimmune lymphoproliferative conditions not recognized on gene sequencing panels. It is important to follow these patients closely for disease recurrence, infections, or development of lymphoma and requires multidisciplinary follow up.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
IMMUNE CHECKPOINT INHIBITOR-RELATED MYASTHENIA GRAVIS, MYOSITIS, HEPATITIS, AND MYOCARDITIS (Convention Center Exhibit Hall: Poster Area 3) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5578;
ICI therapy can cause a spectrum of adverse autoimmune effects. Treatment for cases requiring intensive care includes holding ICI therapy at least temporarily, high-dose corticosteroids, and plasmapheresis or IVIG if symptoms are rapidly progressive or refractory.
- |||||||||| Darzalex (daratumumab) / J&J
A RARE MANIFESTATION OF LIGHT CHAIN AMYLOIDOSIS AND ITS MANAGEMENT (Convention Center Exhibit Hall: Rapid Fire Area 4C) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5515;
Management of AL amyloidosis by itself is complicated, and while Dara-CVD treatment has been shown to successfully lead to sustained hematological complete responses and improvements in organ function, intolerances to combination treatment have been reported. To the best of our knowledge, this is the first case where chylothorax in a patient with AL amyloidosis and concurrent plasma cell dyscrasia was successfully treated with octreotide.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
SOUR AND SWEET: A CASE OF CONCURRENT NEOPLASMS, MALIGNANT AND BENIGN (Convention Center Exhibit Hall: Poster Area 3) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5473;
At this time the patient was started on carboplatin, paclitaxel, and pembrolizumab. Despite incomplete staining results this case demonstrates possible concurrent PEComa and squamous cell lung cancer.
- |||||||||| Rituxan (rituximab) / Roche
RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE DUE TO ANTI-MDA5 ANTIBODY WITHOUT DERMATOMYOSITIS (Convention Center Exhibit Hall: Rapid Fire Area 3B) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5444;
The workup for idiopathic inflammatory myopathies due to anti-MDA5 should be considered in a patient with ILD since patients can present with atypical symptoms like this one. Since it is a rapidly progressive disease, early diagnosis is key to starting treatment and referring patients for lung transplant evaluation.
- |||||||||| Rituxan (rituximab) / Roche
IDIOPATHIC PULMONARY FIBROSIS WITH CONCOMITANT ANCA VASCULITIS (Convention Center Exhibit Hall: Rapid Fire Area 3B) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5441;
Although there are no current societal recommendations for further serologic evaluation in IPF patients, providers should have a high suspicion of concomitant ANCA-associated vasculitis with IPF. Screening high-risk patients for vasculitis, especially for MPO antibodies, should be considered at the time of IPF diagnosis and during follow-up visits.
- |||||||||| Rituxan (rituximab) / Roche
A CASE OF RECURRENT DIFFUSE ALVEOLAR HEMORRHAGE REQUIRING ECMO IN A PATIENT WITH PULMONARY SLE (Convention Center Exhibit Hall: Rapid Fire Area 3B) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5440;
Our patient is a unique case in having SLE with recurrent DAH treated successfully with ECMO therapy on two separate occasions. Her survival provides further evidence that this may be an area warranting of clinical trials and future research.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
PEMBROLIZUMAB-ASSOCIATED DIABETES MELLITUS PRESENTING AS DIABETIC KETOACIDOSIS (Convention Center Exhibit Hall: Rapid Fire Area 2C) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5431;
ICPis have a range of adverse effects that require clinician awareness in both the inpatient and outpatient settings. It is important for outpatient providers to carefully monitor for new onset of diabetes in patients on ICPis and for inpatient providers to recognize DKA as the initial presentation of CIADM.
- |||||||||| Kisqali (ribociclib) / Novartis
FATAL RIBOCICLIB-INDUCED PNEUMONITIS (Convention Center Exhibit Hall: Rapid Fire Area 3C) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5424;
With the increased use of CDK 4/6 inhibitors in breast cancer, physicians should be aware of the associated pulmonary toxicities. Our case highlights the unpredictable onset of pneumonitis as our patient presented 8 months after initiating treatment.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
RECURRENT PNEUMONITIS IN A 72-YEAR-OLD MALE (Convention Center Exhibit Hall: Poster Area 3) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5375;
We have described a case of recurrent pneumonitis in a patient undergoing combination therapy initially with pembrolizumab, pemetrexed, and carboplatin. Early diagnosis of pneumonitis is key so the offending agent can be discontinued and the patient can be started on therapy with steroids.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
PULMONARY OSSIFICATION: WHEN LUNGS GROW BONES, IT BECOMES HARD TO BREATH (Convention Center Exhibit Hall: Poster Area 3) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5374;
Pulmonary ossification presents as a rare phenomenon with few antemortem cases and unclear etiology. While we hypothesize that medication-induced pneumonitis in the setting of COVID-19 may have led to pulmonary ossification, its clinical significance and management remain unclear, warranting further study.
- |||||||||| Rituxan (rituximab) / Roche
RITUXIMAB FOR THE MANAGEMENT OF REFRACTORY THROMBOTIC THROMBOCYTOPENIC PURPURA (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5336;
CASE PRESENTATION: 33-year-old female with a significant PMH of systemic lupus erythematous on chronic prednisone therapy 20mg/day presents to ED with a six-day history of chills, shortness of breath, and pleuritic chest pain. Refractory TTP to pulse dose IV methylprednisolone and plasmapheresis requires once a week Rituximab for four weeks.
- |||||||||| Hemlibra (emicizumab-kxwh) / Roche, Rituxan (rituximab) / Roche
A MISSING FACTOR: A CASE OF AQUIRED HEMOPHILA A (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5327;
Patient underwent three rounds of plasmapheresis, an infusion of rituximab, and was eventually treated with emicizumab. In this case, we had several possible etiologies that could have caused the acquired hemophilia A, though in this case it could not ultimately be identified.
|
